查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947959

注射型HIV治疗药物市场依治疗阶段、通路、最终用户、给药频率及年龄组别划分－全球预测，2026-2032年

Injectable HIV Medication Market by Treatment Line, Distribution Channel, End User, Dosage Frequency, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，注射用 HIV 药物市场规模将达到 47.5 亿美元，到 2026 年将达到 50 亿美元，到 2032 年将达到 75.1 亿美元，复合年增长率为 6.75%。

关键市场统计数据
基准年 2025 47.5亿美元
预计年份：2026年 50亿美元
预测年份 2032 75.1亿美元
复合年增长率 (%) 6.75%

简要概述长效注射抗逆转录病毒如何改变临床实务模式、依从性模式和医疗保健系统物流。

注射型抗逆转录病毒疗法已从临床探索发展成为切实可行的临床选择，重塑了爱滋病毒感染者的治疗策略。与每日口服给药相比，长效製剂具有截然不同的依从性，减轻了患者的用药负担，并为那些难以坚持每日服药的患者提供了一种替代方案。同时，监管部门的核准和不断增长的真实世界临床数据增强了医疗服务提供者对注射疗法的信心，物流基础设施也进行了相应调整，以应对冷藏保管、给药流程和低温运输配送等方面的挑战。

治疗创新、服务提供方式的重新设计和物流投资如何共同重塑了注射型抗逆转录病毒的治疗路径

注射型HIV药物治疗领域已发生变革性转变，主要得益于治疗方法创新、病患偏好变化、给药方式的革新。新型长效整合酶抑制剂和合併用药方案的出现，开启了新的临床路径，使给药频率降低，药物动力学更易预测。因此，临床医师在製定治疗决策时，除了传统的疗效和安全性指标外，也开始考虑治疗方法的便利性和依从性等因素。

检验2025年美国关税调整及其对供应链、采购及定价的影响

2025年美国关税政策为注射用HIV药物的供应链经理、采购主管和全球生产商带来了新的考量。进口关税的提高将影响成品注射剂和原材料的到岸成本结构，因此需要重新评估筹资策略和库存管理。对于营运全球供应链的企业而言，关税凸显了近岸外包、供应商多元化和合约保障措施在降低成本波动方面的重要性。

详细的細項分析揭示了年龄层、治疗方案、给药途径、作用机制、给药频率和生产者趋势如何决定临床和商业性结果。

细分市场洞察揭示了影响产品定位、服​​务设计和市场推广策略的细微临床和商业性动态。在不同年龄组别中，成人和儿童族群在临床试验需求、给药方案和依从性支持需求方面存在差异。儿童药物的采纳往往落后于製剂和安全性的考量，而成人计画则较着重于依从性和长期耐受性。治疗线细分区分第一线、补救和二线应用场景。第一线治疗强调安全性和便利性，补救治疗需要可靠的耐受性数据以及在接受过多种药物治疗的患者中的耐受性，而二线治疗则需要在疗效和既往用药史之间取得平衡。

区域评估比较了管理体制、报销结构和医疗服务模式，这些因素导致了关键区域在采纳率方面的差异

三大区域的区域特征差异显着，进而影响监管路径、报销环境和分销挑战。在美洲，成熟的监管体系和完善的爱滋病治疗网络加速了临床试验的开展和临床医生的熟悉程度，而与支付方的谈判以及公私合营则推动了药物清单编制和准入计划的精细化。该地区通常在产生真实世界证据和快速将新的给药模式整合到临床实践中方面发挥主导作用。

策略竞争概览：创新领导者和区域製造商如何运用配方、分销和伙伴关係策略来扩大注射疗法的可及性

注射型HIV药物的竞争格局呈现大规模综合製药公司和专注于製剂技术、物流和病患支援的专业製药公司并存的局面。领先的生物製药公司已在长效製剂的研发、临床试验和真实世界证据方面投入巨资，以建立临床医生的信任并促进与支付方的沟通。这些公司通常拥有全面的患者支援解决方案、成熟的分销网络和全球监管方面的专业知识，使其能够协调复杂的产品上市流程，并在多个临床试验点开展大规模给药项目。

製造商、医疗服务提供者和支付方应重点关注以下切实可行的策略事项，以加快注射疗法的普及，降低供应链风险，并使循证医学证据的产生与支付模式保持一致。

产业领导者应优先考虑制定整合策略，将临床证据产生和实际服务提供的投资相结合，以最大限度地扩大患者可及性并实现持续应用。这首先要投资于有针对性的真实世界研究和核准后安全性监测，以解决医疗服务提供者和支付方对特定患者群体（包括儿童和既往接受过治疗的患者）的担忧。产生关于耐受性、抗药性模式和长期疗效的可靠证据，可以显着增强医保报销谈判的筹码，并提升医疗服务提供者的信心。

采用透明的综合调查方法，结合相关人员访谈、监管审查、临床文献综述和供应链情境分析，确保研究结果的严谨性。

本研究采用混合方法，结合质性专家访谈、监管文件审查和临床文献综合分析，以全面了解注射型HIV治疗药物。主要研究包括与临床研究人员、医院药局主任、居家医疗计画主任和供应链经理进行结构化访谈，以了解现场操作挑战和推广应用的驱动因素。此外，还对同行评审文章、临床试验报告和监管核准文件进行了有针对性的审查，以确保研究结果与最新的安全性和有效性证据相符。

总之，我们的综合分析强调了证据综合、物流和支付方参与之间的合作是推动肠外疗法产生广泛临床影响的关键因素。

注射型HIV治疗代表着治疗模式的持续转变，它融合了临床创新、新型给药方式以及商业性的复杂性。监管部门的核准、临床经验以及日益增长的实际应用表明，只要相关人员能够解决物流、报销和供应链方面的挑战，这些治疗方法将在特定病患小组中发挥越来越重要的作用。同样，关税和采购趋势也凸显了营运柔软性和积极主动的采购决策对于维持治疗的可及性和可负担性的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依治疗方案分類的注射型HIV药物市场

  • 一线治疗
  • 补救性治疗
  • 二级治疗

9. 按分销管道分類的注射型爱滋病药物市场

  • 在线的
  • 离线

第十章 以最终用户分類的注射型爱滋病药物市场

  • 诊所
  • 居家医疗
  • 医院

11. 依给药频率分類的注射型爱滋病药物市场

  • 每隔一个月
  • 每月一次
  • 季刊

第十二章 按年龄组别分類的注射用爱滋病药物市场

  • 成人版
  • 儿童
  • 老年人

13. 各地区注射用爱滋病药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的注射用爱滋病药物市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国注射用爱滋病药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国注射爱滋病药物市场

第十七章：中国的注射用爱滋病药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim
  • Bristol Myers Squibb Company
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Viatris Inc.
  • ViiV Healthcare Limited
Product Code: MRR-4F7A6D4FB6A9

The Injectable HIV Medication Market was valued at USD 4.75 billion in 2025 and is projected to grow to USD 5.00 billion in 2026, with a CAGR of 6.75%, reaching USD 7.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.75 billion
Estimated Year [2026] USD 5.00 billion
Forecast Year [2032] USD 7.51 billion
CAGR (%) 6.75%

A concise orientation to how long-acting injectable antiretrovirals are changing clinical practice patterns adherence models and health system logistics

Injectable antiretroviral therapies have matured from clinical curiosities into viable clinical practice options, reshaping therapeutic strategies for people living with HIV. Long-acting formulations offer a fundamentally different adherence profile compared with daily oral regimens, reducing pill burden and offering an alternative pathway for patients who struggle with daily dosing. In parallel, regulatory approvals and real-world evidence accumulation have expanded clinician confidence in injectable regimens, while logistical infrastructures have adapted to accommodate refrigerated storage, administration workflows, and cold-chain distribution considerations.

Clinical adoption is being driven by demonstrable patient-centered benefits including reduced adherence variability and potential improvements in quality of life for selected populations. Health systems are responding by investing in clinic workflows, training nursing staff for intramuscular administration, and integrating electronic health record prompts to manage injection schedules. At the same time, payors and procurement teams are evaluating total cost of care implications as they weigh the clinical advantages against administration cost and distribution complexities. Taken together, these developments mark a substantive inflection point for injectable HIV therapeutics and establish a pragmatic foundation for broader commercialization efforts.

How therapeutic innovation alongside service delivery redesign and logistical investments have collectively redefined adoption pathways for injectable antiretrovirals

The landscape for injectable HIV medication has undergone transformative shifts catalyzed by therapeutic innovation, evolving patient preferences, and shifting delivery paradigms. Novel long-acting integrase inhibitors paired with companion agents have opened clinical pathways that prioritize less frequent dosing and predictable pharmacokinetics. As a result, clinicians are reframing treatment decisions to incorporate regimen convenience and adherence dynamics alongside traditional efficacy and safety endpoints.

Concurrently, distribution and administration models have diversified. Hospital-based infusion centers remain essential for complex patients, but an increasing number of clinics and homecare services are being equipped to administer intramuscular injections, driven by patient demand for decentralized care. This decentralization has required investments in cold chain capacity, staff training, and documentation workflows. Moreover, manufacturers and distributors have adapted commercial strategies to emphasize patient support programs, provider education, and logistical partnerships that reduce friction points between prescription and administration. In sum, the combined effect of therapeutic progress and operational adaptation has redefined how stakeholders approach HIV treatment delivery.

An examination of the 2025 United States tariff adjustments and how heightened import duties are reshaping supply chain, procurement, and pricing decisions

The tariff landscape in the United States for 2025 has introduced new considerations for supply chain managers, procurement leads, and global manufacturers of injectable HIV therapies. Increased import duties can influence landed cost structures for finished injectables and raw materials, necessitating a reassessment of sourcing strategies and inventory management. For organizations operating global supply chains, tariffs amplify the importance of nearshoring, supplier diversification, and contractual protections to mitigate cost volatility.

Operational teams are responding by recalibrating production planning, exploring alternate manufacturing footprints, and negotiating volume-based terms to absorb incremental tariff-induced costs. Regulatory affairs and quality leaders are concurrently evaluating the feasibility of localized fill-and-finish operations to reduce cross-border movement of finished product. Importantly, payors and pricing committees are taking a more granular view of net acquisition costs, administration fees, and service-level obligations as they determine product placement and reimbursement pathways. In this environment, companies that proactively align procurement, manufacturing, and commercial contracting stand to preserve margins and sustain access for patients despite tariff pressures.

In-depth segmentation analysis revealing how age cohorts, treatment line, administration setting, mechanism of action, dosing cadence, and manufacturer dynamics determine clinical and commercial outcomes

Segmentation insights reveal nuanced clinical and commercial dynamics that influence product positioning, service design, and go-to-market strategy. Across age group distinctions, adult and pediatric populations present divergent clinical trial requirements, dosing paradigms, and adherence support needs; pediatric adoption often lags due to formulation and safety considerations, while adult programs focus on broader adherence and long-term tolerability. Treatment line segmentation differentiates first line, salvage, and second line use cases, with first-line positioning emphasizing safety and simplicity, salvage scenarios requiring robust resistance data and tolerability in heavily treated patients, and second-line options balancing efficacy against prior exposure.

Distribution channel choices between hospital pharmacy and retail pharmacy drive different procurement rhythms, administrative responsibilities, and patient access models, as hospital pharmacies typically support complex care pathways while retail pharmacies enable community-based pickup and coordination with clinic administration. Patient type differentiation between treatment experienced and treatment naive cohorts shapes messaging and clinical trial design; treatment experienced patients often require resistance-tailored approaches and monitoring, whereas treatment naive populations prioritize tolerability and initiation convenience. End user context-clinic, homecare, and hospital-dictates administration setting, cold chain demands, and staffing models, with clinic and homecare settings increasingly central to decentralization strategies. Drug mechanism distinctions among integrase inhibitors, NNRTIs, NRTIs, and protease inhibitors inform resistance profiles, combinability, and regimen sequencing decisions. Dosage frequency options of bi-monthly, monthly, and quarterly administration create differentiated adherence profiles and inventory management requirements. Manufacturer dynamics including established biopharmaceutical innovators and diversified generics manufacturers influence pricing strategies, patient support program availability, and distribution partnerships, all of which shape competitive positioning and access pathways.

A comparative regional assessment highlighting how regulatory regimes, reimbursement structures, and healthcare delivery models drive differentiated adoption across major global territories

Regional dynamics vary markedly across the three principal geographies, shaping regulatory pathways, reimbursement environments, and distribution challenges. In the Americas, a mature regulatory infrastructure and well-established HIV care networks accelerate trial uptake and clinician familiarity, while payor negotiations and private-public partnerships drive nuanced formulary placement and access programs. This region often leads in real-world evidence generation and rapid integration of new administration models into clinical practice.

Europe, Middle East & Africa presents a complex tapestry of regulatory regimes, procurement mechanisms, and health system capacities. In parts of Europe, centralized reimbursement frameworks and strong post-market surveillance foster careful but steady adoption, whereas Middle Eastern and African markets reveal heterogeneous infrastructure readiness, variable cold chain capacity, and differing priorities around domestic manufacturing and donor-supported procurement. Asia-Pacific encompasses rapidly evolving demand centers with diverse payer models, from highly centralized procurement systems to market-driven segments. In several Asia-Pacific markets, strong generic manufacturing capabilities and innovative distribution partnerships support alternative commercialization models that can accelerate access when regulatory alignment occurs. Across all regions, local healthcare delivery models, reimbursement policies, and capacity for clinic-based versus home-based administration are decisive factors in determining how injectable therapies are adopted and scaled.

Strategic competitive overview describing how innovation leaders and regional manufacturers deploy formulation, distribution, and partnership strategies to expand injectable therapy access

The competitive landscape for injectable HIV therapies reflects a mix of large integrated pharmaceutical companies and specialized manufacturers focusing on formulation, logistics, and patient support. Leading biopharmaceutical organizations have invested heavily in long-acting formulations, clinical programs, and real-world evidence generation to underpin clinician confidence and payer conversations. These firms typically bring comprehensive patient support solutions, established distribution networks, and access to global regulatory expertise, enabling them to coordinate complex product launches and scale administration programs across multiple care settings.

At the same time, established generic and specialty manufacturers play a growing role by offering alternative pricing models, localized manufacturing, and partnerships that expand distribution reach. Their capabilities in cost-effective production and flexible commercial agreements can facilitate broader patient access, particularly in price-sensitive or procurement-driven environments. Across the competitive set, strategic alliances between originators and local partners, licensing deals that enable regional manufacturing, and investments in distribution infrastructure are common, reflecting a pragmatic approach to accelerating availability while managing commercial and operational risks. Taken together, these company-level dynamics underscore a shift toward collaborative commercialization models as stakeholders seek to balance innovation, affordability, and access.

Actionable strategic priorities for manufacturers, providers, and payors to accelerate access, de-risk supply chains, and align evidence generation with payment models for injectable therapies

Industry leaders should prioritize integrated strategies that align clinical evidence generation with pragmatic service delivery investments to maximize patient access and sustainable uptake. First, invest in targeted real-world studies and post-authorization safety monitoring that address clinician and payor concerns for specific patient cohorts, including pediatric populations and treatment experienced individuals. Generating robust evidence for tolerability, resistance patterns, and long-term outcomes will materially strengthen reimbursement negotiations and provider confidence.

Second, develop flexible distribution and administration models that accommodate clinic-based, homecare, and hospital settings, and design patient support programs that reduce missed appointments and manage storage requirements. Third, mitigate tariff and supply chain risk through diversified manufacturing footprints, nearshoring where feasible, and contractual safeguards with suppliers and distributors to preserve margin and continuity of supply. Fourth, engage payors early with value dossiers that articulate total cost of care implications and address administration fee structures. Finally, pursue collaborative partnerships-licensing, co-commercialization, or strategic alliances-that combine therapeutic innovation with regional manufacturing and distribution expertise to accelerate access while controlling costs. Executed together, these actions will allow organizations to translate clinical innovation into durable, equitable access for patients.

A transparent mixed-methods research design integrating stakeholder interviews, regulatory review, clinical literature synthesis, and supply chain scenario analysis to ensure rigorous findings

The research described here employed a mixed-methods approach combining qualitative expert interviews, regulatory document review, and synthesis of clinical literature to construct a comprehensive understanding of injectable HIV therapies. Primary research included structured conversations with clinical investigators, hospital pharmacy directors, homecare program leads, and supply chain managers to capture frontline operational challenges and adoption drivers. These interviews were complemented by a targeted review of peer-reviewed publications, clinical trial reports, and regulatory approval documents to ensure alignment with the latest safety and efficacy evidence.

Secondary analysis incorporated public filings, patent landscapes, and company disclosures to map manufacturer strategies, distribution partnerships, and manufacturing footprints. Supply chain risk analysis used scenario-based assessments to examine tariff impacts, cold chain requirements, and potential mitigation pathways. Throughout the process, data synthesis emphasized triangulation across sources and explicit documentation of assumptions to support transparency. The methodology prioritized replicability and contextual depth, enabling stakeholders to evaluate strategic levers and operational trade-offs with confidence.

A conclusive synthesis emphasizing coordinated evidence, logistics, and payer engagement as the decisive factors for translating injectable therapies into scalable clinical impact

Injectable HIV therapies represent a durable shift in treatment paradigms that combine clinical innovation with new delivery and commercial complexities. The accumulation of regulatory approvals, clinical experience, and real-world adoption signals that these therapies will occupy an expanding role for selected patient groups, provided stakeholders address logistical, reimbursement, and supply chain challenges. Equally, tariff and procurement dynamics underscore the need for operational flexibility and proactive sourcing decisions to maintain access and affordability.

Successful adoption will hinge on coordinated action across evidence generation, distribution design, and payer engagement. Organizations that invest early in pragmatic clinical data, build versatile administration networks encompassing clinics and homecare, and strategically manage manufacturing footprints will be best positioned to translate therapeutic promise into patient impact. The path forward is collaborative: aligning manufacturers, providers, payors, and service partners around shared outcomes and practical implementation strategies will determine the pace and equity of access to injectable HIV treatments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Injectable HIV Medication Market, by Treatment Line

  • 8.1. First Line
  • 8.2. Salvage
  • 8.3. Second Line

9. Injectable HIV Medication Market, by Distribution Channel

  • 9.1. Online
  • 9.2. Offline

10. Injectable HIV Medication Market, by End User

  • 10.1. Clinic
  • 10.2. Homecare
  • 10.3. Hospital

11. Injectable HIV Medication Market, by Dosage Frequency

  • 11.1. Bi Monthly
  • 11.2. Monthly
  • 11.3. Quarterly

12. Injectable HIV Medication Market, by Age Group

  • 12.1. Adult
  • 12.2. Pediatric
  • 12.3. Geriatric

13. Injectable HIV Medication Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Injectable HIV Medication Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Injectable HIV Medication Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Injectable HIV Medication Market

17. China Injectable HIV Medication Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Accord Healthcare Ltd.
  • 18.7. Amneal Pharmaceuticals, Inc.
  • 18.8. Aurobindo Pharma Ltd.
  • 18.9. Boehringer Ingelheim
  • 18.10. Bristol Myers Squibb Company
  • 18.11. Cipla Ltd.
  • 18.12. Dr. Reddy's Laboratories Ltd.
  • 18.13. Genentech, Inc.
  • 18.14. Gilead Sciences, Inc.
  • 18.15. Hetero Labs Limited
  • 18.16. Johnson & Johnson
  • 18.17. Lupin Limited
  • 18.18. Merck & Co., Inc.
  • 18.19. Mylan N.V.
  • 18.20. Sun Pharmaceutical Industries Ltd.
  • 18.21. Teva Pharmaceutical Industries Ltd.
  • 18.22. Theratechnologies Inc.
  • 18.23. Viatris Inc.
  • 18.24. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INJECTABLE HIV MEDICATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INJECTABLE HIV MEDICATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SALVAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SALVAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SALVAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY BI MONTHLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY BI MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY BI MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY MONTHLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY QUARTERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY QUARTERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY QUARTERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 110. GCC INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 128. G7 INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 134. NATO INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL INJECTABLE HIV MEDICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA INJECTABLE HIV MEDICATION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)